PharmaTelevision teams up with EBD Group to offer Television Interview and Media Training

Oct 15 2009NewsGuard 100/100 Score

PharmaTelevision(R), the authoritative channel for the pharmaceutical, biotechnology and related industries, today announced that it is teaming up with the EBD Group to offer delegates at BIO-Europe a Television Interview and Media Training.

Dr Fintan Walton, CEO of PharmaVentures - the company behind PharmaTelevision - said, "Standing out and attaining share of voice is becoming increasingly difficult in the crowded world of biopharma partnering. Effective communication that makes an impact is critical for attracting partners and winning deals. That is why we have devised this unique package for BIO-Europe delegates."

Dr Walton continues, "By offering media training, we are helping to make our interviewees excellent communicators through the medium of television."

Source:

PharmaTelevision

Posted in: Miscellaneous News

Tags: ,

Comments (0)

Suggested Reading

UChicago scientists develop a new approach to study snoRNAs
AI-designed drug ISM5939 granted IND clearance for cancer clinical trials
Utilizing process Raman in optimizing cultivated meat production
CAR T cell therapy breakthroughs bring new hope for treating solid tumors
Engineered virus-like particles evolve for superior gene delivery efficiency
Obesity crisis in the U.S. expected to worsen by 2050
ProductLife Group (PLG) Acquires Halloran
Researchers develop new approach to effectively deliver therapeutics into the brain

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study shows how a single defective BRCA1 gene accelerates cancer development